Mexican funding agency forces out early-career researchers.

Science

Inés Gutiérrez Jaber is a journalist in Mexico City.

Published: June 2021

Download full-text PDF

Source
http://dx.doi.org/10.1126/science.372.6546.1024DOI Listing

Publication Analysis

Top Keywords

mexican funding
4
funding agency
4
agency forces
4
forces early-career
4
early-career researchers
4
mexican
1
agency
1
forces
1
early-career
1
researchers
1

Similar Publications

The Jalap Roots: A Herbal Legacy from the Neotropics to the World.

J Ethnopharmacol

January 2025

Departamento de Farmacia, Facultad de Química, Universidad Nacional Autónoma de México, Ciudad Universitaria, 04510, Mexico City, Mexico. Electronic address:

Etnopharmacological Relevance: The Convolvulaceae or morning glory family, with about 2000 species in the world's Tropics and subtropics, stands out among the plants used in traditional medicine. Medicinal plant complexes with important purgative properties have been developed in Mexico and Brazil from members of the genera Ipomoea and Operculina with storage roots. Popularly known as the jalap roots, their resin glycosides cause purgative and laxative activities that facilitate bowel movements.

View Article and Find Full Text PDF

Background: Tackling social impacts derived from gender disparities is a pathway to universal health coverage (UHC). Gender intersects with other factors behind social and health inequalities, exacerbates them and influences health systems' performance. However, there is scarcity of gender-based studies that assess the social and economic impacts of non-communicable diseases (NCDs).

View Article and Find Full Text PDF

Introduction: Rheumatoid arthritis (RA) is a progressive autoimmune inflammatory disease. According to the European League Against Rheumatism (EULAR), the stages of RA progression include pre-RA, preclinical RA, inflammatory arthralgia, arthralgia with positive antibodies, arthralgia suspected of progressing to RA, undifferentiated arthritis and finally established RA. According to the Community Oriented Program for Control of Rheumatic Diseases (COPCORD), the prevalence of RA in Mexico is 1.

View Article and Find Full Text PDF

Background and objective The use of ivermectin and nitazoxanide in the treatment of coronavirus disease 2019 (COVID-19) has been a subject of controversy. In this study, we aimed to describe our clinical experience in treating COVID-19 patients with these drugs in Mexico. Material and methods The study involved out- and inpatient clinical assessments of COVID-19 patients conducted in Mexico City from September 2020 to November 2021.

View Article and Find Full Text PDF

Comparison in the adult congenital heart disease severity classification of ACC/AHA and ESC guidelines in a 3,459 Mexican population.

Int J Cardiol Congenit Heart Dis

March 2024

Surgical and Medical Cardiovascular Specialties Direction, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.

Background: Latin American registries of clinical and demographic profiles of ACHD are scarce. International guidelines classify disease complexity with different approaches. With these two regards, a registry was carried out to examine factors associated with mortality and to compare severity classifications in our population.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!